Current Therapeutic Strategies and Prospects for EGFR Mutation-Positive Lung Cancer Based on the Mechanisms Underlying Drug Resistance

The discovery of activating mutations in the epidermal growth factor receptor (EGFR) gene and the development of EGFR tyrosine kinase inhibitors (TKIs) have led to a paradigm shift in the treatment of non-small cell lung cancer (NSCLC). EGFR mutation-positive NSCLC is common in East Asia, and approx...

Descripción completa

Detalles Bibliográficos
Autores principales: Tsubata, Yukari, Tanino, Ryosuke, Isobe, Takeshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8619018/
https://www.ncbi.nlm.nih.gov/pubmed/34831415
http://dx.doi.org/10.3390/cells10113192

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8619018/
https://www.ncbi.nlm.nih.gov/pubmed/34831415
http://dx.doi.org/10.3390/cells10113192

Ejemplares similares